Pfizer Inc. is threatening legal action at an attempt by Novo Nordisk A/S to scupper its acquisition of Metsera Inc., with an unsolicited $9 billion offer for the anti-obesity specialist. That trumps Pfizer’s agreed bid made in September, which valued New York-based Metsera at $7.3 billion. Read More
Two in five preclinical studies on subarachnoid hemorrhage (SAH) published in peer-reviewed scientific journals contain problematic images. A team of researchers from Radboud University Medical Center, who had previously identified several such cases, analyzed the literature in this field to assess the scope of the issue. They found that 40% of the studies included suspicious images. Read More
John Crowley doesn’t worry about where his kids’ toys are made, but he told the Senate Health, Education, Labor and Pensions Committee that he does care where their medicines are made. His concerns, as a father and as president/CEO of the Biotechnology Innovation Organization, are becoming more urgent, he testified at an Oct. 29 HELP hearing on the future of biotech in the U.S. Read More
The Korea Biotechnology Industry Organization on Oct. 30 welcomed the bilateral trade deal between the U.S. and South Korea announced during U.S. President Donald Trump’s state visit alongside the Asia-Pacific Economic Cooperation forum in Gyeongju, South Korea. Read More
Lumosa Therapeutics Co. Ltd.’s intravenous odatroltide (LT-3001) met the primary endpoints in a phase IIb trial in China in patients with acute ischemic stroke, paving the way for a pivotal phase III study. Read More
The BioWorld Biopharmaceutical Index extended its rebound through August and September, closing the third quarter (Q3) slightly in positive territory after losing ground earlier in the year. Read More
Celltrion Inc. announced Oct. 29 the signing of an $87.75 million joint drug R&D agreement with AI and spatial transcriptome-based biotech Portrai Inc. Read More
What trends in life sciences have defined the last three decades? BioWorld Editor Nuala Moran picks monoclonal antibodies as the most significant. “They are the cornerstone around which medical biotechnology as a sector has been built.” Read More
Biopharmas raising money in public or private financings, including: Creative Medical Technology, Eliksa, Genprex, Maplight, Pinetree, Rarity. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: Biogen, Ferring, GC Cell, Hyloris, Iaso, I-Mab, Kadimastem, NLS, Orion, Relief, Samsung Bioepis. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Biomarin, Exousia, Merck, Mimetech. Read More
